We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-15.93%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$307M
AUM Growth
-$111M
Cap. Flow
-$25.2M
Cap. Flow %
-8.21%
Top 10 Hldgs %
66.99%
Holding
55
New
8
Increased
13
Reduced
15
Closed
15

Top Buys

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$26.3M
2
CPRX
Catalyst Pharmaceutical
CPRX
+$16.1M
3
OCUL icon
Ocular Therapeutix
OCUL
+$2.82M
4
IGMS
IGM Biosciences
IGMS
+$1.68M
5
GOSS icon
Gossamer Bio
GOSS
+$1.6M

Top Sells

Rank Stock Value
1
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$9.79M
2
TELA icon
TELA Bio
TELA
+$7.71M
3
CBAY
Cymabay Therapeutics
CBAY
+$6.21M
4
TBPH icon
Theravance Biopharma
TBPH
+$5.63M
5
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
+$5.57M

Sector Composition

Rank Sector Weight
1 Healthcare 98.99%
2 Miscellaneous 1.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LRMR icon
26
Larimar Therapeutics
LRMR
$421M
$3.35M 1.09%
848,500
-541,500
-39% -$2.05M
NYXH
27
Nyxoah
NYXH
$160M
$3.12M 1.01%
441,896
-3,104
-0.7% -$24.3K
BDSX icon
28
Biodesix
BDSX
$300M
$3.04M 0.99%
+22,779
New +$632K
IOVA icon
29
Iovance Biotherapeutics
IOVA
$3.74B
$2.78M 0.9%
610,000
+189,000
+45% +$1.23M
APLT
30
DELISTED
Applied Therapeutics
APLT
$2.22M 0.72%
+893,000
New +$1.47M
IGMS
31
DELISTED
IGM Biosciences
IGMS
$2.18M 0.71%
261,000
+197,500
+311% +$1.68M
CDXS icon
32
Codexis
CDXS
$182M
$2.11M 0.69%
1,118,900
+443,900
+66% +$1.04M
VSTM icon
33
Verastem
VSTM
$668M
$1.72M 0.56%
211,400
+109,400
+107% +$1.05M
PGEN icon
34
Precigen
PGEN
$2.57B
$1.32M 0.43%
+928,500
New +$1.32M
TCON
35
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$848K 0.28%
238,225
– –
XERS icon
36
Xeris Biopharma Holdings
XERS
$1.57B
$725K 0.24%
+390,000
New +$893K
FBIO icon
37
Fortress Biotech
FBIO
$93.4M
$581K 0.19%
133,333
-87,334
-40% -$599K
KZR
38
DELISTED
Kezar Life Sciences
KZR
$506K 0.16%
42,500
+32,620
+330% +$578K
RLMD icon
39
Relmada Therapeutics
RLMD
$482M
$90K 0.03%
+30,000
New +$89.1K
ACAD icon
40
Acadia Pharmaceuticals
ACAD
$5.12B
– –
-217,000
Closed -$5.2M
ATXS
41
DELISTED
Astria Therapeutics
ATXS
– –
-305,000
Closed -$2.54M
BDTX icon
42
Black Diamond Therapeutics
BDTX
$130M
– –
-275,000
Closed -$1.39M
CYTK icon
43
Cytokinetics
CYTK
$10.8B
– –
-130,000
Closed -$4.24M
FOCL
44
EDAP TMS S.A.
FOCL
$199M
– –
-380,000
Closed -$3.5M
FULC icon
45
Fulcrum Therapeutics
FULC
$294M
– –
-143,600
Closed -$474K
KPTI icon
46
Karyopharm Therapeutics
KPTI
$44M
– –
-119,000
Closed -$3.2M
NTLA icon
47
Intellia Therapeutics
NTLA
$1.84B
– –
-120,000
Closed -$4.89M
PRQR icon
48
ProQR Therapeutics
PRQR
$327M
– –
-653,000
Closed -$1.06M
STRO icon
49
Sutro Biopharma
STRO
$353M
– –
-30,700
Closed -$1.43M
STXS icon
50
Stereotaxis
STXS
$147M
– –
-3,074,995
Closed -$2.95M
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q3 2023 Portfolio in Review

As of Q3 2023, Opaleye Management held 55 positions worth $307M, down 26% from $418M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Opaleye Management withdrew a net $25.2M in Q3 2023, closing 15 positions and reducing 15 holdings. Its most notable exit was Cymabay Therapeutics, an estimated $6.21M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in TG Therapeutics worth $15.8M.

  • Opaleye Management's largest Q3 2023 buy was TG Therapeutics: 1,890,000 shares worth $15.8M.
  • Opaleye Management added most to Ocular Therapeutix in Q3 2023, an estimated $2.82M increase.
  • Opaleye Management's biggest Q3 2023 reduction was Crinetics Pharmaceuticals, cutting an estimated $9.79M.
  • Opaleye Management fully exited Cymabay Therapeutics in Q3 2023, selling an estimated $6.21M.
  • Opaleye Management's ten largest holdings make up 67% of its $307M portfolio in Q3 2023.
  • Opaleye Management opened 8 new positions and closed 15 in Q3 2023.
  • Opaleye Management's portfolio value fell 26% quarter-over-quarter to $307M.

Based on Opaleye Management's 13F filing for Q3 2023, filed 15 Nov 2023.